Rigel Pharmaceuticals, Inc.
RIGL
$42.58
$1.794.39%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -22.60% | 10.28% | 20.73% | 25.59% | 176.01% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -22.60% | 10.28% | 21.19% | 25.59% | 176.01% |
| Cost of Revenue | 98.55% | 26.76% | 45.70% | -14.79% | 35.68% |
| Gross Profit | -37.79% | 5.06% | 15.13% | 39.56% | 217.12% |
| SG&A Expenses | 11.57% | 10.59% | 1.60% | 7.00% | 4.31% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 35.84% | 15.71% | 13.90% | -0.51% | 11.51% |
| Operating Income | -61.42% | -6.95% | 39.12% | 102.19% | 13,569.57% |
| Income Before Tax | -60.68% | 1.27% | 49.22% | 122.37% | 5,923.50% |
| Income Tax Expenses | 1,605.96% | 4,520.00% | -27,949.15% | -- | -- |
| Earnings from Continuing Operations | -71.00% | -24.39% | 1,769.22% | 124.62% | 5,887.67% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -71.00% | -24.39% | 1,769.22% | 124.62% | 5,887.67% |
| EBIT | -61.42% | -6.95% | 39.12% | 102.19% | 13,569.57% |
| EBITDA | -60.42% | -6.69% | 37.73% | 97.88% | 5,721.70% |
| EPS Basic | -72.02% | -26.87% | 1,711.54% | 119.17% | 5,778.19% |
| Normalized Basic EPS | -62.07% | -2.05% | 44.63% | 116.96% | 5,811.44% |
| EPS Diluted | -73.17% | -30.16% | 1,598.73% | 108.57% | 5,566.67% |
| Normalized Diluted EPS | -63.51% | -6.54% | 35.58% | 104.86% | 5,724.25% |
| Average Basic Shares Outstanding | 3.67% | 3.39% | 3.18% | 2.49% | 1.91% |
| Average Diluted Shares Outstanding | 7.75% | 8.35% | 10.05% | 8.54% | 3.49% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |